JP2020528889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528889A5 JP2020528889A5 JP2020502955A JP2020502955A JP2020528889A5 JP 2020528889 A5 JP2020528889 A5 JP 2020528889A5 JP 2020502955 A JP2020502955 A JP 2020502955A JP 2020502955 A JP2020502955 A JP 2020502955A JP 2020528889 A5 JP2020528889 A5 JP 2020528889A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered
- aryl
- hydroxy
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 Cc1c(*)c(I)c[o]1 Chemical compound Cc1c(*)c(I)c[o]1 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762536352P | 2017-07-24 | 2017-07-24 | |
| US62/536,352 | 2017-07-24 | ||
| US201762573935P | 2017-10-18 | 2017-10-18 | |
| US62/573,935 | 2017-10-18 | ||
| PCT/US2018/043330 WO2019023145A1 (en) | 2017-07-24 | 2018-07-23 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528889A JP2020528889A (ja) | 2020-10-01 |
| JP2020528889A5 true JP2020528889A5 (https=) | 2021-09-02 |
| JP7349981B2 JP7349981B2 (ja) | 2023-09-25 |
Family
ID=63143409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502955A Active JP7349981B2 (ja) | 2017-07-24 | 2018-07-23 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11370763B2 (https=) |
| EP (1) | EP3658538B1 (https=) |
| JP (1) | JP7349981B2 (https=) |
| CN (1) | CN111094242B (https=) |
| ES (1) | ES2949404T3 (https=) |
| WO (1) | WO2019023145A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2988798T3 (es) | 2017-07-24 | 2024-11-21 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| EP3692020A1 (en) | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
| AU2019299444A1 (en) * | 2018-07-03 | 2021-01-14 | Novartis Ag | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a NLRP3 antagonist |
| JP2021529186A (ja) * | 2018-07-03 | 2021-10-28 | ノバルティス アーゲー | Ｎｌｒｐ調節剤 |
| KR20210053910A (ko) | 2018-08-15 | 2021-05-12 | 인플라좀 리미티드 | 신규한 설폰아마이드유레아 화합물 |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| ES3042546T3 (en) * | 2018-11-13 | 2025-11-21 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| US12134611B2 (en) | 2018-11-13 | 2024-11-05 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| WO2020102574A1 (en) * | 2018-11-16 | 2020-05-22 | Novartis Inflammasome Research, Inc. | The compounds and compositions for treating conditions associated with nlrp activity |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| GB201905265D0 (en) | 2019-04-12 | 2019-05-29 | Inflazome Ltd | Inflammasome inhibition |
| EP3986879B1 (en) | 2019-06-21 | 2024-10-02 | AC Immune SA | Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators |
| WO2021002887A1 (en) * | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| JP2022545400A (ja) | 2019-08-16 | 2022-10-27 | インフレイゾーム リミテッド | Ｎｌｒｐ３阻害剤として有用な大環状スルホニル尿素誘導体 |
| WO2021032588A1 (en) | 2019-08-16 | 2021-02-25 | Inflazome Limited | Macrocyclic sulfonylamide derivatives useful as nlrp3 inhibitors |
| US20220289692A1 (en) | 2019-09-06 | 2022-09-15 | Inflazome Limited | Nlrp3 inhibitors |
| WO2021165245A1 (en) | 2020-02-18 | 2021-08-26 | Inflazome Limited | Compounds |
| JP2023518829A (ja) | 2020-03-25 | 2023-05-08 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 糖尿病の治療方法 |
| AU2021291065B2 (en) | 2020-06-19 | 2025-06-26 | Ac Immune Sa | Dihydrooxazole and thiourea or urea derivatives modulating the nlrp3 inflammasome pathway |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| CN116917282A (zh) * | 2021-05-10 | 2023-10-20 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| CN118541366A (zh) | 2021-12-22 | 2024-08-23 | Ac免疫有限公司 | 二氢噁唑衍生物化合物 |
| EP4554945A1 (en) | 2022-07-14 | 2025-05-21 | AC Immune SA | Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway |
| AU2023313032A1 (en) | 2022-07-28 | 2025-01-23 | Ac Immune Sa | Novel compounds |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
| WO2025133307A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153625A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153624A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
| CN119680348A (zh) * | 2025-02-05 | 2025-03-25 | 上海惠志环保科技有限公司 | 一种应用于含高浓度二氯甲烷废气处理方法及其系统 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA929699B (en) * | 1991-12-20 | 1994-06-14 | Lilly Co Eli | Sulfonimidamides |
| SI3259253T1 (sl) * | 2015-02-16 | 2020-07-31 | The University Of Queensland | Sulfonilsečnine in sorodne spojine ter njihova uporaba |
| US11447460B2 (en) * | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| US11339136B2 (en) * | 2016-04-18 | 2022-05-24 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| AU2019299444A1 (en) * | 2018-07-03 | 2021-01-14 | Novartis Ag | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a NLRP3 antagonist |
-
2018
- 2018-07-23 JP JP2020502955A patent/JP7349981B2/ja active Active
- 2018-07-23 WO PCT/US2018/043330 patent/WO2019023145A1/en not_active Ceased
- 2018-07-23 US US16/632,850 patent/US11370763B2/en active Active
- 2018-07-23 ES ES18752375T patent/ES2949404T3/es active Active
- 2018-07-23 EP EP18752375.8A patent/EP3658538B1/en active Active
- 2018-07-23 CN CN201880050914.5A patent/CN111094242B/zh active Active
-
2024
- 2024-07-22 US US18/779,915 patent/US20240391884A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528889A5 (https=) | ||
| JP2020537657A5 (https=) | ||
| JP2019519598A5 (https=) | ||
| JP2019515952A5 (https=) | ||
| KR102083857B1 (ko) | 신규 치환된 인다졸, 그의 제조 방법, 상기 신규 치환된 인다졸을 함유하는 제약 제제, 및 약물을 제조하기 위한 상기 신규 치환된 인다졸의 용도 | |
| JP2019518071A5 (https=) | ||
| ES2927777T3 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP | |
| HRP20251344T1 (hr) | SPOJEVI I PRIPRAVCI ZA LIJEČENJE STANJA POVEZANIH S AKTIVNOŠĆU NLRP-a | |
| HRP20240521T1 (hr) | Spojevi i pripravci za liječenje stanja povezanih s aktivnošću nlrp | |
| JPWO2020086732A5 (https=) | ||
| JP2010540508A5 (https=) | ||
| JPWO2020102096A5 (https=) | ||
| TW201841919A (zh) | 作為抗病毒劑之稠合吲唑吡啶酮化合物 | |
| JP2019510787A5 (https=) | ||
| JP2019529444A5 (https=) | ||
| JP2014503574A5 (https=) | ||
| JP2010513285A5 (https=) | ||
| JP2012524053A5 (https=) | ||
| JP2014515346A5 (https=) | ||
| CA2575777A1 (en) | Compositions and methods for treatment of colitis using methimazole and/or cyclic thione derivatives | |
| JP2021502387A5 (https=) | ||
| TW201737943A (zh) | 使用fasn抑制劑之方法 | |
| JPWO2020102576A5 (https=) | ||
| JP2022505562A (ja) | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 | |
| EP3817815A1 (en) | Nlrp modulators |